Perla Breccia

• How can expanding the target space beyond the common splice modulators unlock new opportunities for targeting novel disease areas

• What strategies are enabling the design of chemically diverse scaffolds to overcome current limitations in the ligand design space

• Are we overdependent on nonsense-mediated decay and can reducing this reliance drive broaden therapeutic applicability of splice modulators

• What lessons can be drawn from recent investments and platform development to guide future innovation in RNA-targeted small molecules